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S U M M A R Y
Clostridium tertium is rare in a human clinical specimen and its pathogenicity is often uncertain.
However, the organism has been increasingly recognized as a cause of bacteremia and other infections in
immunocompromised patients, especially those with hematologic malignancies. The diagnosis and
treatment of C. tertium are difﬁcult due to its growth pattern, micromorphology, and antibiotic
resistance. The organism can easily be misidentiﬁed as Gram-positive aerobic rods such as Bacillus
species, usually considered as a contaminant. Furthermore, it is not covered by empirical treatment with
many broad-spectrum antibiotics. Here we report a case of breakthrough bacteremia due to C. tertium
that occurred in a patient with acute leukemia and neutropenic fever, who was treated with an empirical
regimen of ceftazidime and amikacin. The bacterium was rapidly identiﬁed by new mass spectrometry
technology (MALDI-TOF MS) and the patient recovered under meropenem and vancomycin treatment,
without complications.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Clostridium tertium is an endospore-forming Gram-positive
bacillus, which may grow aerobically and does not produce
exotoxins. It can be isolated in soil and the gastrointestinal tract of
humans and other animals, but rarely occurs in clinical samples.1
To date, its role as a human pathogen remains uncertain.2 The
organism grows easily on conventional media, but misidentiﬁca-
tion can occur due to its aerotolerance and Gram-variable
appearance.1 In contrast to most other clostridial species,
treatment can be a challenge, since resistance to various antibiotics
including third- and fourth-generation cephalosporins, seems to
be common.1
We report a case of breakthrough bacteremia in a patient with
neutropenic fever under treatment with a standard broad-
spectrum antibiotic regimen.
2. Case report
A 47-year-old woman presented with a history of 5 days of dry
cough and sharp left-sided thoracic pain accompanied by fever up* Corresponding author. Tel.: +56 2 2210 1006; fax: +56 2 2210 1153.
E-mail addresses: thomas.weitzel@gmail.com, tweitzel@alemana.cl (T. Weitzel).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.03.005to 38 8C, malaise, and headache. Two months previously she had
been treated with levoﬂoxacin for maxillary sinusitis; otherwise
she reported no relevant previous illnesses. A physical examina-
tion was unremarkable except for left upper quadrant abdominal
pain on deep palpation. Chest radiography showed no pathological
ﬁndings. Laboratory evaluation revealed a blood leukocyte count of
78.4  109/l with 97% blasts and an absolute neutrophil count of
0.784  109 cells/l, platelet count of 12  109/l, hemoglobin of
10.2 mg/dl, and C-reactive protein (CRP) of 6.02 mg/dl. Computed
tomography scanning of the abdomen and pelvis demonstrated
splenomegaly of 14 cm. Based on these test results the patient was
hospitalized with the suspicion of acute leukemia. Urine and blood
cultures were taken and empiric antibiotic therapy with ceftazi-
dime and amikacin was initiated. Further hematologic and genetic
studies conﬁrmed the diagnosis of Philadelphia chromosome-
negative common acute lymphoblastic leukemia. Microbiological
cultures remained negative, and after 2 days of antibiotic
treatment, the patient was afebrile and started chemotherapy
with fractionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone (Hyper-CVAD). During the following days she
developed progressive neutropenia. Therefore, the antibiotic
regimen was maintained and the patient remained afebrile and
clinically stable. On day 17 after the start of chemotherapy, the
patient presented with a fever up to 40 8C; she was hemodynami-
cally stable and without other symptoms except transientses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Gram-stain of Clostridium tertium in blood culture medium.
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0.1  109/l, platelets of 37  109/l, hemoglobin of 9.9 g/dl, and CRP
of 17.3 mg/dl. Two sets of blood cultures were drawn and the
antimicrobial treatment was changed to meropenem, vancomycin,
and voriconazole.
Within 16 to 21 h, all four blood culture media became positive
(BacT/Alert 3D system with FAN aerobic bottles; bioMe´rieux,
Marcy l’Etoile, France). Gram staining revealed large Gram-
variable bacilli, partly growing in short chains (Figure 1). Overnight
aerobic cultivation on 5% sheep blood agar (bioMe´rieux) at 35 8C
showed small, semitransparent, shiny colonies of Gram-variable
rods. Examination by mass spectrometry identiﬁed the strain as
Clostridium tertium with a high level of reliability; Microﬂex LT
(Bruker Daltonics, Bremen, Germany) gave an identiﬁcation log
score of 2.517 (above 2.0 is considered reliable for species
identiﬁcation) and Vitek MS (bioMe´rieux) reported the same
result with 99.9% certainty. The following day, this result was
conﬁrmed by conventional biochemical methods (VITEK 2
Compact; bioMe´rieux). The organism also grew under anaerobic
conditions in similar but bigger colonies and microscopically with
terminal spores. Antibiotic susceptibility testing by agar dilution
technique performed at the national reference laboratory (Insti-
tuto de Salud Pu´blica, Santiago, Chile) demonstrated sensitivity to
metronidazole (minimum inhibitory concentration (MIC) 1.0 mg/
ml) and moxiﬂoxacin (MIC 0.25 mg/ml), but resistance to
ceftriaxone (MIC >32 mg/ml).
The patient remained clinically stable and became afebrile after
3 days. Treatment with meropenem and vancomycin was
maintained until day 12 of the regimen, when the patient, who
had a history of penicillin allergy, developed an urticarial rash and
meropenem was replaced by amikacin. This antibiotic therapy was
continued for a further 2 weeks. The patient recovered from the
neutropenia and continued her chemotherapy in the following
weeks without recurrence of C. tertium bacteremia.
3. Discussion
Clostridium tertium has long been considered apathogenic, since
it only rarely occurred in mixed infections of traumatic wounds. In
recent years the organism has been isolated in cases of bacteremia,
spontaneous bacterial peritonitis, enterocolitis, meningitis, septic
arthritis, necrotizing fasciitis, post-traumatic brain abscess, and
complicated pneumonia in mono- or polymicrobial infections.2,3 In
cases of clostridial bacteremia, C. tertium is the second most
frequently isolated species after Clostridium perfringens.1 The mainrisk factors seem to be intestinal mucosal injury, neutropenia, and
exposure to beta-lactam antibiotics.4 Similar to Clostridium difﬁcile,
the use of broad-spectrum antibiotics such as third-generation
cephalosporins might predispose to intestinal colonization with C.
tertium. Patients with hematologic malignancies combine several
of these risk factors, and cases of C. tertium bacteremia in those
patients have been described in association with diarrhea, colonic
bleeding, and peri-anal cellulitis.4 However, as our case demon-
strates, such distinct intestinal symptoms might also be absent. In
cases of neutropenic fever, international guidelines recommend
the empirical use of broad-spectrum beta-lactam antibiotics as
monotherapy or in combination with other drugs such as
aminoglycosides.5 Empirical treatment for neutropenic fever often
does not cover C. tertium and our case highlights that breakthrough
bacteremia might occur. In these situations, a rapid identiﬁcation
and communication between the microbiologist and clinician is
crucial.1 Because of its micromorphology and growth pattern, C.
tertium is often mistaken for Bacillus or Lactobacillus species, both
considered as contaminants or apathogenic. Therefore thorough
identiﬁcation of this species is critical. Unfortunately, traditional
identiﬁcation of anaerobes is time-consuming and cumbersome.
New methods based on mass spectrometry such as MALDI-TOF MS
(matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry), which have been developed for the rapid identiﬁ-
cation of bacterial strains, might offer new possibilities for this
group of microorganisms.6,7 In our case, the two commercial
systems that are available at the moment, Microﬂex LT and Vitek
MS, were able to identify C. tertium reliably and faster than
traditional methods.
The treatment of C. tertium infection is complicated due to
resistance to various antibiotics, including various beta-lactam
antibiotics (such as third- and fourth-generation cephalosporins),
clindamycin, daptomycin, and cotrimoxazole.1–3 Older reports
state resistance to metronidazole, but this has not been conﬁrmed
in more recent publications. Available data indicate sensitivity to
vancomycin, carbapenems, and quinolones. Still, studies examin-
ing sufﬁcient numbers of strains are lacking. As in our case, clinical
resolution of bacteremia due to C. tertium occurs rapidly if
adequate treatment is chosen.4
Our case highlights that C. tertium is able to cause breakthrough
bacteremia in patients with neutropenic fever receiving standard
empiric antibiotics and that rapid identiﬁcation of this unusual
pathogen can be achieved by new MALDI-TOF technology.
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